<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>News on Schering-Plough Corporation</title><link href="http://earningsandlosses.com/topic/schering-plough-corporation" rel="alternate"></link><id>http://earningsandlosses.com/topic/schering-plough-corporation</id><updated>2010-10-29T07:30:30Z</updated><entry><title>Merck 3Q profit plunges 90 percent on deal charges</title><link href="http://earningsandlosses.com/earnings-and-losses/merck-3q-profit-plunges-90-percent-deal-charges-3483476a" rel="alternate"></link><updated>2010-10-29T07:30:30Z</updated><author><name>AP News</name></author><id>tag:earningsandlosses.com,2010-10-29:/earnings-and-losses/merck-3q-profit-plunges-90-percent-deal-charges-3483476a/</id><summary type="html">&lt;div id="subtitle"&gt;&lt;a title="Merck &amp; Co. Inc." href="/topic/Merck+%26+Co.+Inc." &gt;Drugmaker Merck&lt;/a&gt;'s 3Q profit plunges 90 percent on charges from &lt;a title="Schering-Plough Corporation" href="/topic/Schering-Plough+Corporation" &gt;Schering-Plough&lt;/a&gt; acquisition&lt;/div&gt;&lt;div&gt;&lt;p&gt;Merck &amp;amp; Co. posted a 90 percent drop in third-quarter profit, due to large charges for its $41.1 billion acquisition last year of Schering-Plough Corp. and a legal reserve set up because of a federal investigation.&lt;/p&gt;&lt;p&gt;...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Mergers and Acquisitions"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="India"></category><category term="China"></category><category term="Europe"></category><category term="Asia"></category><category term="Claritin"></category><category term="Schering-Plough Corporation"></category><category term="Singulair"></category><category term="Merck &amp; Co. Inc."></category><category term="Russia"></category><category term="Vioxx"></category><category term="East Asia"></category><category term="South Asia"></category><category term="Whitehouse Station"></category><category term="Dr. Scholl's Foot Care Products"></category><category term="Coppertone Sun Care Products"></category><category term="Januvia"></category><category term="Richard Clark"></category></entry><entry><title>Schering-Plough Corporation&amp;#160;Q2 2009 Earnings Call Transcript</title><link href="http://earningsandlosses.com/earnings-and-losses/scheringplough-corporation23160q2-2009-earnings-call-transcript-2486590a" rel="alternate"></link><updated>2010-10-22T07:18:41Z</updated><author><name>SeekingAlpha</name></author><id>tag:earningsandlosses.com,2010-10-22:/earnings-and-losses/scheringplough-corporation23160q2-2009-earnings-call-transcript-2486590a/</id><summary type="html">...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Clinical Trials"></category><category term="Animal Diseases"></category><category term="United States"></category><category term="European Union"></category><category term="China"></category><category term="Turkey"></category><category term="U.S. Securities and Exchange Commission"></category><category term="Goldman Sachs Group Inc."></category><category term="Barclays plc"></category><category term="Japan"></category><category term="Boston"></category><category term="Credit Suisse Group"></category><category term="Europe"></category><category term="Canada"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="Claritin"></category><category term="Schering-Plough Corporation"></category><category term="Remeron"></category><category term="Russia"></category><category term="Remicade"></category><category term="East Asia"></category><category term="Tim Anderson"></category><category term="Leerink Swann &amp; Co. Inc."></category><category term="Schering AG"></category><category term="NV Organon"></category><category term="Catherine Arnold"></category><category term="Fred Hassan"></category><category term="Janet Barth"></category><category term="Anthony Butler"></category><category term="Seamus Fernandez"></category><category term="Steve Scala"></category><category term="Chris Schott"></category><category term="Rebetol"></category><category term="Jami Rubin"></category><category term="Simponi"></category><category term="Thomas Koestler"></category><category term="Raul Kohan"></category><category term="Carrie Cox"></category><category term="JPMorgan Chase &amp; Co."></category><category term="Robert Bertolini"></category><category term="Generally Accepted Accounting Principles"></category><category term="Dulera"></category><category term="Bob Bertolini"></category><category term="Tom Koestler"></category><category term="Noxafil Iv"></category></entry><entry><title>Merck sees 57 percent drop in first-quarter profit</title><link href="http://earningsandlosses.com/earnings-and-losses/merck-sees-57-percent-drop-firstquarter-profit-337969a" rel="alternate"></link><updated>2010-04-16T14:56:43Z</updated><author><name>AP News</name></author><id>tag:earningsandlosses.com,2010-04-16:/earnings-and-losses/merck-sees-57-percent-drop-firstquarter-profit-337969a/</id><summary type="html">&lt;div id="subtitle"&gt;&lt;a title="Merck &amp;amp; Co. Inc." href="/topic/Merck+%26+Co.+Inc." &gt;Drugmaker Merck&lt;/a&gt; posts 57 percent drop in first-quarter profit on lower sales, partner revenue&lt;/div&gt;&lt;div&gt;&lt;p&gt;Drugmaker Merck &amp;amp;amp;amp; Co. on Tuesday posted a 57 percent drop in first-quarter profit, falling short of expectations and sending its stock down, as the global recession and other factors cut sales of its drugs and joint venture income.&lt;/p&gt;&lt;p&gt;Last year's quarter also benefited from a one-time pre...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Research and Development"></category><category term="Migraine Medications"></category><category term="Contagious and Infectious Diseases"></category><category term="Cholesterol"></category><category term="Medical Treatments and Procedures"></category><category term="Vaccines"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="New Jersey"></category><category term="United Kingdom"></category><category term="Credit Suisse Group"></category><category term="Europe"></category><category term="Schering-Plough Corporation"></category><category term="Singulair"></category><category term="Merck &amp; Co. Inc."></category><category term="AstraZeneca Group"></category><category term="Gardasil"></category><category term="Vytorin"></category><category term="Zetia"></category><category term="University of Massachusetts Amherst"></category><category term="Western Europe"></category><category term="Fosamax"></category><category term="Thomson Reuters Corporation"></category><category term="Whitehouse Station"></category><category term="Leerink Swann &amp; Co. Inc."></category><category term="Catherine Arnold"></category><category term="Januvia"></category><category term="Richard Clark"></category><category term="Janumet"></category><category term="Seamus Fernandez"></category><category term="Medarex Inc."></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Analysts look for news on Merck tie-up, key drugs</title><link href="http://earningsandlosses.com/earnings-and-losses/analysts-news-merck-tieup-key-drugs-310706a" rel="alternate"></link><updated>2010-09-01T12:15:00Z</updated><author><name>AP News</name></author><id>tag:earningsandlosses.com,2010-09-01:/earnings-and-losses/analysts-news-merck-tieup-key-drugs-310706a/</id><summary type="html">&lt;div id="subtitle"&gt;Analysts looking for news on Merck tie-up with &lt;a title="Schering-Plough Corporation" href="/topic/Schering-Plough+Corporation" &gt;Schering-Plough&lt;/a&gt;, sales of key drugs in Q1&lt;/div&gt;&lt;div&gt;&lt;p&gt;Merck &amp;amp;amp;amp; Co., a Dow component and the world's No. 8 drug maker by revenue, reports earnings for the first quarter on Tuesday morning. The following is a summary of key developments and analyst opinion related to the period.&lt;/p&gt;&lt;p&gt;OVERVIEW: Last month, Merck, the maker of asthma and...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Partnerships"></category><category term="Allergies"></category><category term="Arthritis"></category><category term="Rheumatoid Arthritis"></category><category term="Autoimmune Disorders"></category><category term="Contagious and Infectious Diseases"></category><category term="Cholesterol"></category><category term="Respiratory Medicine"></category><category term="Asthma"></category><category term="Medical Treatments and Procedures"></category><category term="Vaccines"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Schering-Plough Corporation"></category><category term="Singulair"></category><category term="Gardasil"></category><category term="Vytorin"></category><category term="Zetia"></category><category term="Cozaar"></category><category term="Remicade"></category><category term="Vioxx"></category><category term="Clinical Immunology"></category><category term="Leerink Swann &amp; Co. Inc."></category><category term="Januvia"></category><category term="Hyzaar"></category><category term="Insmed Inc."></category><category term="Chris Schott"></category><category term="Cardiovascular Medicine"></category><category term="JPMorgan Chase &amp; Co."></category><category term="Immunotherapy"></category><category term="Muscle and Skeletal Health"></category></entry><entry><title>Merck, Schering-Plough top forecasts on cost cuts</title><link href="http://earningsandlosses.com/earnings-and-losses/merck-scheringplough-top-forecasts-cost-cuts-139579a" rel="alternate"></link><updated>2010-04-16T17:17:49Z</updated><author><name>AP News</name></author><id>tag:earningsandlosses.com,2010-04-16:/earnings-and-losses/merck-scheringplough-top-forecasts-cost-cuts-139579a/</id><summary type="html">&lt;p&gt;&lt;div id="subtitle"&gt;Partner drugmakers Merck, &lt;a title="Schering-Plough Corporation" href="/topic/Schering-Plough+Corporation" &gt;Schering-Plough&lt;/a&gt; top forecasts on cost cuts despite light revenues&lt;/div&gt;&lt;div&gt;&lt;p&gt;Drugmakers Merck &amp;amp;amp;amp; Co. and partner Schering-Plough Corp. both posted fourth-quarter results Tuesday that topped analysts' expectations, sending their shares up, but revenues from their crucial cholesterol franchise plunged.&lt;/p&gt;&lt;p&gt;Both companies beat profit expectations prima...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Economic Issues"></category><category term="Recessions and Depressions"></category><category term="Contagious and Infectious Diseases"></category><category term="Cholesterol"></category><category term="Medical Treatments and Procedures"></category><category term="Vaccines"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="New Jersey"></category><category term="Wall Street"></category><category term="Credit Suisse Group"></category><category term="Claritin"></category><category term="Zyrtec"></category><category term="Schering-Plough Corporation"></category><category term="Singulair"></category><category term="Gardasil"></category><category term="Vytorin"></category><category term="Zetia"></category><category term="Cozaar"></category><category term="Remicade"></category><category term="Fosamax"></category><category term="Vioxx"></category><category term="Whitehouse Station"></category><category term="Steve Brozak"></category><category term="WBB Securities LLC"></category><category term="Schering AG"></category><category term="NV Organon"></category><category term="Catherine Arnold"></category><category term="Richard Clark"></category><category term="Hyzaar"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Schering-Plough Reports Financial Results for 2008 Fourth Quarter, Full Year</title><link href="http://earningsandlosses.com/earnings-and-losses/scheringplough-reports-financial-results-2008-fourth-quarter-full-year-2985643a" rel="alternate"></link><updated>2010-10-23T19:22:04Z</updated><author><name>Drugs.com</name></author><id>tag:earningsandlosses.com,2010-10-23:/earnings-and-losses/scheringplough-reports-financial-results-2008-fourth-quarter-full-year-2985643a/</id><summary type="html">...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Partnerships"></category><category term="Joint Ventures"></category><category term="Research and Development"></category><category term="Corporate Accounting"></category><category term="Financial Markets"></category><category term="Forex"></category><category term="Technology"></category><category term="Medical Technology"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Japan"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="Schering-Plough Corporation"></category><category term="Merck &amp; Co. Inc."></category><category term="Remicade"></category><category term="Bayer AG"></category><category term="East Asia"></category><category term="NV Organon"></category><category term="Fred Hassan"></category><category term="Thomas Koestler"></category><category term="Private Securities Litigation Reform Act"></category><category term="Generally Accepted Accounting Principles"></category><category term="Schering-Plough's Securities and Exchange Commission"></category></entry><entry><title>China Biotech Week in Review: Earnings, Earnings, Earnings</title><link href="http://earningsandlosses.com/earnings-and-losses/china-biotech-week-review-earnings-earnings-earnings-2244080a" rel="alternate"></link><updated>2010-10-21T09:03:02Z</updated><author><name>SeekingAlpha</name></author><id>tag:earningsandlosses.com,2010-10-21:/earnings-and-losses/china-biotech-week-review-earnings-earnings-earnings-2244080a/</id><summary type="html">...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Sciences"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="China"></category><category term="Boston"></category><category term="Jefferies Group Inc."></category><category term="Asia"></category><category term="Schering-Plough Corporation"></category><category term="Shanghai"></category><category term="East Asia"></category><category term="Sichuan Province"></category><category term="China Sky One Medical Inc."></category><category term="China Medical Technologies Inc."></category><category term="Covance Inc."></category><category term="3SBio Inc."></category><category term="American Oriental Bioengineering Inc."></category><category term="Sinovac Biotech Ltd."></category><category term="AMAG Pharmaceuticals Inc."></category><category term="New York Stock Exchange"></category><category term="NYSE Amex Equities"></category><category term="Ge Li"></category><category term="WuXi PharmaTech Inc."></category><category term="Generally Accepted Accounting Principles"></category><category term="SiBiono GeneTech Co. Ltd."></category><category term="Shanghai Pharmaceutical Co. Ltd."></category><category term="Gendicine"></category><category term="BMP Sunstone Corporation"></category><category term="Tongjitang Chinese Medicines Company"></category><category term="Benda Pharmaceutical Inc."></category></entry><entry><title>Merck tops expectations, Schering misses</title><link href="http://earningsandlosses.com/earnings-and-losses/merck-tops-expectations-schering-misses-1256902a" rel="alternate"></link><updated>2010-09-22T14:12:06Z</updated><author><name>AP News</name></author><id>tag:earningsandlosses.com,2010-09-22:/earnings-and-losses/merck-tops-expectations-schering-misses-1256902a/</id><summary type="html">&lt;div id="subtitle"&gt;Partners Merck, &lt;a title="Schering-Plough Corporation" href="/topic/Schering-Plough+Corporation" &gt;Schering-Plough&lt;/a&gt; Post Sharply Different Results&lt;/div&gt;&lt;div&gt;&lt;p&gt;Pharmaceutical companies Schering-Plough Corp. and &lt;a title="Merck &amp;amp; Co. Inc." href="/topic/Merck+%26+Co.+Inc." &gt;Merck &amp;amp; Co.&lt;/a&gt; posted strong sales Monday from their joint venture on cholesterol drugs, but otherwise their third-quarter earnings reports &amp;amp;#8212; and investor reaction &amp;amp;#8212; were striki...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Financial Markets"></category><category term="Stock Prices"></category><category term="Trials"></category><category term="Civil Trials"></category><category term="Contagious and Infectious Diseases"></category><category term="Cholesterol"></category><category term="Medical Treatments and Procedures"></category><category term="Vaccines"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Wall Street"></category><category term="Bank of America Corporation"></category><category term="Goldman Sachs Group Inc."></category><category term="Schering-Plough Corporation"></category><category term="Singulair"></category><category term="Merck &amp; Co. Inc."></category><category term="Gardasil"></category><category term="Vytorin"></category><category term="Zetia"></category><category term="Cozaar"></category><category term="Fosamax"></category><category term="Vioxx"></category><category term="Nasonex"></category><category term="Clarinex"></category><category term="Whitehouse Station"></category><category term="Steve Brozak"></category><category term="WBB Securities LLC"></category><category term="Schering AG"></category><category term="NV Organon"></category><category term="Januvia"></category><category term="Fred Hassan"></category><category term="Hyzaar"></category><category term="James Kelly"></category><category term="Chris Schott"></category><category term="Cardiovascular Medicine"></category><category term="Peter Kellogg"></category><category term="Immunotherapy"></category><category term="Stock Markets"></category></entry><entry><title>Partners Merck, Schering-Plough post sharply different results</title><link href="http://earningsandlosses.com/earnings-and-losses/partners-merck-scheringplough-post-sharply-results-1256807a" rel="alternate"></link><updated>2010-09-22T14:12:05Z</updated><author><name>AP Features</name></author><id>tag:earningsandlosses.com,2010-09-22:/earnings-and-losses/partners-merck-scheringplough-post-sharply-results-1256807a/</id><summary type="html">&lt;div&gt;&lt;p&gt;Pharmaceutical companies &lt;a title="Schering-Plough Corporation" href="/topic/Schering-Plough+Corporation" &gt;Schering-Plough Corp.&lt;/a&gt; and &lt;a title="Merck &amp;amp; Co. Inc." href="/topic/Merck+%26+Co.+Inc." &gt;Merck &amp;amp; Co.&lt;/a&gt; posted strong sales Monday from their joint venture on cholesterol drugs, but otherwise their third-quarter earnings reports &amp;amp;#8212; and investor reaction &amp;amp;#8212; were strikingly different.&lt;/p&gt;&lt;p&gt;&lt;a title="Whitehouse Station" href="/topic/Whitehouse+Station" &gt;W...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Financial Markets"></category><category term="Stock Prices"></category><category term="Trials"></category><category term="Civil Trials"></category><category term="Contagious and Infectious Diseases"></category><category term="Cholesterol"></category><category term="Medical Treatments and Procedures"></category><category term="Vaccines"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Wall Street"></category><category term="Bank of America Corporation"></category><category term="Goldman Sachs Group Inc."></category><category term="Schering-Plough Corporation"></category><category term="Singulair"></category><category term="Merck &amp; Co. Inc."></category><category term="Gardasil"></category><category term="Vytorin"></category><category term="Zetia"></category><category term="Cozaar"></category><category term="Fosamax"></category><category term="Vioxx"></category><category term="Nasonex"></category><category term="Clarinex"></category><category term="Whitehouse Station"></category><category term="Steve Brozak"></category><category term="WBB Securities LLC"></category><category term="Schering AG"></category><category term="NV Organon"></category><category term="Januvia"></category><category term="Fred Hassan"></category><category term="Hyzaar"></category><category term="James Kelly"></category><category term="Chris Schott"></category><category term="Cardiovascular Medicine"></category><category term="Peter Kellogg"></category><category term="Immunotherapy"></category><category term="Stock Markets"></category></entry></feed>
